2014•International Journal of Infectious DiseasesOpen access
Long-term therapy with adefovir dipivoxil for HBeAg positive chronic hepatitis B patients with various baseline biochemical levels: Results from 4 years adefovir dipivoxil treatment
Lin Zhuang, Jae‐Seek You, L. Kong, Y.L. Li, H. Lei, Yuzhi Ma, H.Y. Chen, Hongyao Liu, X. Feng, S.J. Ma, Jian Huang, Yangzi Che, Qianqiang Wang, L. Chen, Shuang Yan
Open full text 1 citations
Abstract
Background: Since the introduction of nucleos(t)ide analogues (NUCs), there has been marked improvement in the care of the patients with chronic hepatitis B, resulting in increased survival. Adefovir dipivoxil (ADV) has shown efficacy and safety in a broad range of populations with chronic hepatitis B over 48 to 96 weeks. This study reports the 192-week long-term efficacy data with ADV treatment in nucleoside-naive HBeAg-positive chronic hepatitis B.